Resverlogix Corp. (TSE:RVX) – Research analysts at Zacks Investment Research reduced their FY2018 earnings per share (EPS) estimates for Resverlogix Corp. in a report released on Wednesday. Zacks Investment Research analyst J. Vandermosten now forecasts that the biotechnology company will earn ($0.51) per share for the year, down from their previous estimate of ($0.26). Zacks Investment Research also issued estimates for Resverlogix Corp.’s FY2019 earnings at ($0.45) EPS.

TRADEMARK VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at

Resverlogix Corp. (TSE RVX) traded up 1.40% during midday trading on Friday, hitting $1.45. 24,807 shares of the company traded hands. The stock has a 50 day moving average of $1.38 and a 200 day moving average of $1.88. The stock’s market cap is $161.25 million. Resverlogix Corp. has a 12-month low of $1.14 and a 12-month high of $2.47.

Resverlogix Corp. Company Profile

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer’s disease and orphan diseases.

Earnings History and Estimates for Resverlogix Corp. (TSE:RVX)

Receive News & Stock Ratings for Resverlogix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix Corp. and related stocks with our FREE daily email newsletter.